Brooks Laboratories share news, announcements and annual reports
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Brooks Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹60.56down ₹3.28 (5.14%)BSE ₹60.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹63.84.
30 Oct: open ₹65.80, high ₹66.00, low ₹59.70
52-week range of traded prices to 30 Oct 2026
₹36.30Low, 30 Mar 2026₹116.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹178 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.45
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,79557.7% delivered
Brooks Laboratories share news and announcements
454 announcements, routine notices left out, newest first. Page 8 of 10.
Aug 2016
Jun 2016
May 2016
Apr 2016
Mar 2016
Feb 2016
12 Feb · Change in Company Secretary/Compliance Officer
Dec 2015
Nov 2015
Oct 2015
1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2015
Aug 2015
May 2015
29 May · Results
16 May · Code of Conduct under SEBI(PIT) Reg., 2015
Apr 2015
Feb 2015
3 Feb · Board meeting
To consider and to approve, inter alia, Unaudited Financial Results for the quarter and nine months ended 31st December, 2014.
Jan 2015
14 Jan · Legal
Exchange had sought clarification from Brooks Laboratories Limited with respect to a news item captioned "Brooks Labs, honchos fined Rs. 12 cr". The Company has clarified that "As per SEBI website, the Adjudicating Officer has passed an Order dated January 12, 2015 against the Company and its directors/officials. As per the Order, a penalty of Rs 1 crore is imposed on the Company and Rs 10.8 crores on five other entities comprising of three directors and two former officials of the Company. We have yet not been served with the copy of the said Order either by post or email. We may point out that the Order is culmination of the Ad-Interim Ex-Parte Order passed against the Company on December 28, 2011 and a subsequent Confirmatory Order in this regard on July 09, 2013, which are already in public domain. We would like to submit that we do not agree with the findings of the Order and we would be contesting the same before Securities Appellate Tribunal in due course".13 Jan · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to recent news item captioned "Brooks Labs, honchos fined Rs.12 cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
4 Dec · Legal
Exchange had sought clarification from Brooks Laboratories Limited with respect to a news item captioned "Orders passed against DLF, 7 others". The Company has clarified that "It is a matter of record that SEBI had passed an Ad Interim Ex-Parte Order against the Company on December 28, 2011. Subsequently, SEBI passed a Confirmatory Order in this regard on July 09, 2013. Apart from the aforesaid Orders, no other Order has been passed against the Company by SEBI. We would like to submit that this is not a new development as the aforesaid Orders were passed some time ago and the information is already in public domain".3 Dec · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to recent news item captioned "Orders passed against DLF, 7 others". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
Oct 2014
29 Oct · Board meeting
To consider and to approve, inter alia, Unaudited Financial Results for the quarter and half year ended 30th September, 2014.
Sep 2014
Aug 2014
13 Aug · Board meeting
Appointment of Mr. Ankit Parekh as the Company Secretary Cum Compliance Officer of the Company w.e.f. August 01st,2014.11 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2014
May 2014
29 May · Results